Publication: Five-(Tetradecyloxy)-2-furoic acid alleviates cholangiocarcinoma growth by inhibition of cell-cycle progression and induction of apoptosis
2
Issued Date
2021-07-01
Resource Type
ISSN
17917530
02507005
02507005
Other identifier(s)
2-s2.0-85109335128
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Anticancer Research. Vol.41, No.7 (2021), 3389-3400
Suggested Citation
Piyanard Boonnate, Ryusho Kariya, Paksiree Saranaruk, Ubon Cha'on, Kanlayanee Sawanyawisuth, Sarawut Jitrapakdee, Seiji Okada, Kulthida Vaeteewoottacharn Five-(Tetradecyloxy)-2-furoic acid alleviates cholangiocarcinoma growth by inhibition of cell-cycle progression and induction of apoptosis. Anticancer Research. Vol.41, No.7 (2021), 3389-3400. doi:10.21873/anticanres.15126 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/76120
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Five-(Tetradecyloxy)-2-furoic acid alleviates cholangiocarcinoma growth by inhibition of cell-cycle progression and induction of apoptosis
Abstract
Background/Aim: Cholangiocarcinoma (CCA), a biliary cancer, is a health problem worldwide. The major problem in CCA treatment presents limited options. To date, targeting cancer metabolism is a promising anti-cancer strategy. To elucidate the functional importance of lipid metabolism in CCA, de novo lipogenesis was inhibited using 5-(tetradecyloxy)-2-furoic acid (TOFA), an acetyl CoA carboxylase inhibitor. Materials and Methods: Antiproliferative effects of TOFA were determined both in vitro and in vivo. Its inhibitory effect on cell-cycle and apoptosis was investigated by flow cytometry and western blot analysis of relevant markers. Results: TOFA inhibited CCA cell growth, induced cell-cycle progression accompanied by apoptosis in a dose-dependent manner. Induction of p21, and caspase-3, -8, and -9 cleavages, while down-regulation of cyclin B1 and cyclin D1 were observed in TOFA-treated cells. The therapeutic potential was demonstrated in vivo. Conclusion: De novo lipogensis is essential for CCA cell growth and is an alternative target for CCA treatment.